2. Academic Validation
  3. Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor

Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor

  • Bioorg Med Chem Lett. 2013 Dec 15;23(24):6789-93. doi: 10.1016/j.bmcl.2013.10.018.
Hui Xiong 1,  Melinda Foulk,  Lisa Aschenbrenner,  Jun Fan,  Choi-Lai Tiong-Yip,  Kenneth D Johnson,  Demetri Moustakas,  Paul R Fleming,  Dean G Brown,  Minli Zhang,  Douglas Ferguson,  Dedong Wu,  Qin Yu
Affiliations

Affiliation

  • 1 Infection Innovative Medicine, AstraZeneca Pharmaceuticals, 35 Gatehouse Lane, Waltham, MA 02451, USA.
PMID: 24211022 DOI: 10.1016/j.bmcl.2013.10.018
Abstract

Targeting viral polymerases has been a proven and attractive strategy for Antiviral drug discovery. Herein we describe our effort in improving the Antiviral activity and physical properties of a series of benzothienoazepine compounds as respiratory syncytial virus (RSV) RNA polymerase inhibitors. The Antiviral activity and spectrum of this class was significantly improved by exploring the amino substitution of the pyridine ring, resulting in the discovery of the most potent RSV A polymerase inhibitors reported to date.

Keywords

Antiviral; Polymerase inhibitor; Respiratory syncytial virus.

Figures